

Vimian's Nomination Committee proposes Pia Marions as new Board member

The Nomination Committee in Vimian Group AB (publ) proposes that Pia Marions is appointed new Board member at the Annual General Meeting in April 2025. Furthermore, the Nomination Committee has been informed that Robert Belkic and Frida Westerberg have declined re-election.

Pia Marions (b. 1963) has significant operational experience from the financial services sector, including as CFO of Skandia Group, Folksam and Carnegie Group, and long experience from Board work in the healthcare and life science sector, including Vitrolife and Unilabs. She has also held leading positions at Royal Bank of Scotland, Skandia Liv, Länsförsäkringar Liv and the Swedish Financial Supervisory Authority, and has experience as an authorised public accountant. She is currently chairman of the Board of Directors in Skandiabanken Aktiebolag (publ) and Impilo Healthcare AB as well as board member in Duni AB (publ), Vitrolife AB (publ), Carnegie Group, Sophiahemmet Rehab Center AB and Unilabs Group Holding APS. Pia Marions is independent of Vimian, its executive management and the major shareholders.

The Nomination Committee proposes re-election of Theodor Bonnier, Gabriel Fitzgerald, Petra Rumpf and Magnus Welander. Magnus Welander is proposed to be re-elected as chairman of the Board of Directors.

The Nomination Committee's complete proposal will be presented in the notice to the 2025 Annual General Meeting. The Nomination Committee comprises Håkan Håkansson (Fidelio Capital), Suzanne Sandler (Handelsbanken Fonder), Caroline Sjösten (Swedbank Robur Fonder) and Magnus Welander (Chairman of the Board in Vimian Group).

The Annual General Meeting in Vimian Group AB (publ) will be held on 29 April 2025.

For further information, please contact:

Maria Dahllöf Tullberg

Head of IR, Communications & Sustainability

maria.tullberg@vimian.com

+46 736 26 88 86

About Vimian

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company's Certified Adviser.

Attachments

[Vimian's Nomination Committee proposes Pia Marions as new Board member](#)